Abstract
In recent years, target therapies to specific molecular alterations present in non-small cell lung cancer (NSCLC) patients have been discovered and have shown superior efficacy compared to non-targeted treatments. Among the molecular alterations identified in NSCLC, the anaplastic lymphoma tyrosine kinase (ALK) receptor, present in 3.4% of patients, is one of the therapeutic targets. The aim of this study was to estimate in monetary terms the value of the benefit of ALK diagnosis in NSCLC in Spain.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annals of oncology : official journal of the European Society for Medical Oncology
Paper Title
Journal
Date
